Bioventus Inc. (NYSE:BVS) Shares Sold by Counterpoint Mutual Funds LLC

Counterpoint Mutual Funds LLC lowered its position in shares of Bioventus Inc. (NYSE:BVS) by 26.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 37,645 shares of the company’s stock after selling 13,704 shares during the period. Counterpoint Mutual Funds LLC’s holdings in Bioventus were worth $395,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Charles Schwab Investment Management Inc. grew its stake in shares of Bioventus by 38.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock worth $4,662,000 after purchasing an additional 109,359 shares in the last quarter. Segall Bryant & Hamill LLC acquired a new position in shares of Bioventus during the third quarter worth $4,515,000. Point72 Asset Management L.P. acquired a new position in shares of Bioventus during the third quarter worth $788,000. JPMorgan Chase & Co. grew its stake in shares of Bioventus by 228.3% during the third quarter. JPMorgan Chase & Co. now owns 253,740 shares of the company’s stock worth $3,032,000 after purchasing an additional 176,442 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Bioventus by 38.8% during the third quarter. State Street Corp now owns 676,501 shares of the company’s stock worth $8,084,000 after purchasing an additional 189,216 shares in the last quarter. Institutional investors and hedge funds own 62.94% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on BVS. JPMorgan Chase & Co. raised shares of Bioventus from an “underweight” rating to a “neutral” rating and boosted their price target for the company from $12.00 to $13.00 in a research report on Tuesday, December 17th. Canaccord Genuity Group reissued a “buy” rating and issued a $15.00 price target on shares of Bioventus in a research report on Monday.

Insider Activity

In related news, SVP Anthony D’adamio sold 4,380 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $10.19, for a total transaction of $44,632.20. Following the completion of the transaction, the senior vice president now directly owns 118,178 shares of the company’s stock, valued at $1,204,233.82. This represents a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Mark Leonard Singleton sold 10,733 shares of the stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $10.53, for a total transaction of $113,018.49. Following the transaction, the chief financial officer now directly owns 105,162 shares of the company’s stock, valued at $1,107,355.86. This represents a 9.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,932 shares of company stock valued at $512,511. Insiders own 32.90% of the company’s stock.

Bioventus Price Performance

Shares of BVS opened at $9.80 on Tuesday. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The stock has a market cap of $795.32 million, a PE ratio of -16.07 and a beta of 0.86. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The firm has a fifty day moving average price of $10.08 and a 200 day moving average price of $11.02.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.